[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Nurexone Biologic Inc (NRX.VN)

Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 49,705
  • Shares Outstanding, K 92,046
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,384 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 17.89
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $0.02 on 06/01/26
  • Next Earnings Date 09/02/26 [--]
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.435 +24.14%
on 08/05/26
0.700 -22.86%
on 08/20/26
+0.085 (+18.68%)
since 07/28/26
3-Month
0.435 +24.14%
on 08/05/26
0.700 -22.86%
on 08/20/26
-0.100 (-15.62%)
since 05/28/26
52-Week
0.435 +24.14%
on 08/05/26
1.140 -52.63%
on 09/16/25
-0.280 (-34.15%)
since 08/28/25

Most Recent Stories

More News
NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results

TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc.  (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biotechnology company developing...

NRX.VN : 0.540 (+9.09%)
NRXBF : 0.3395 (-11.10%)
NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biotechnology company developing...

NRX.VN : 0.540 (+9.09%)
NRXBF : 0.3395 (-11.10%)
NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”),...

NRX.VN : 0.540 (+9.09%)
NRXBF : 0.3395 (-11.10%)
NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy

Proposed share consolidation of up to 30:1 intended to support potential U.S. exchange listing and broaden investor appeal TORONTO and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic...

NRX.VN : 0.540 (+9.09%)
NRXBF : 0.3395 (-11.10%)
NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy

Proposed share consolidation of up to 30:1 intended to support potential U.S. exchange listing and broaden investor appeal

NRX.VN : 0.540 (+9.09%)
NRXBF : 0.3395 (-11.10%)
NurExone Announces Closing of C$1,066,078 Private Placement

TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing...

NRX.VN : 0.540 (+9.09%)
NRXBF : 0.3395 (-11.10%)
NurExone Announces Closing of C$1,066,078 Private Placement

TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”),...

NRX.VN : 0.540 (+9.09%)
NRXBF : 0.3395 (-11.10%)
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model

TORONTO and HAIFA, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (" NurExone " or the " Company ") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based...

NRX.VN : 0.540 (+9.09%)
NRXBF : 0.3395 (-11.10%)
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model

Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls, providing additional preclinical biological support for previously reported...

NRX.VN : 0.540 (+9.09%)
NRXBF : 0.3395 (-11.10%)
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership

TORONTO and HAIFA, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (" NurExone " or the " Company ") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based...

NRX.VN : 0.540 (+9.09%)
NRXBF : 0.3395 (-11.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy...

See More

Key Turning Points

3rd Resistance Point 0.600
2nd Resistance Point 0.570
1st Resistance Point 0.555
Last Price 0.540
1st Support Level 0.510
2nd Support Level 0.480
3rd Support Level 0.465

See More

52-Week High 1.140
Fibonacci 61.8% 0.871
Fibonacci 50% 0.788
Fibonacci 38.2% 0.704
Last Price 0.540
52-Week Low 0.435

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.